RxDoctor Payments Data

Dexter Sun

New York, NYNPI 1508066705

Payments from drug & device makers

$12,155in general payments, 2019–2025

Across 612 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lundbeck LLC$1K
  • Biogen$810
  • Lilly USA, LLC$698
  • UCB, Inc.$583
  • EMD Serono, Inc.$562
  • plus $6K from 34 others

What the payments were for

  • Food & beverage$12,155100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate34$81,476
RexultiBrexpiprazole12$19,831
Memantine Hcl ErMemantine Hcl81$4,236
Zolmitriptan12$756
Gabapentin40$746
Levetiracetam28$502
Quetiapine Fumarate30$481
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$430
Donepezil Hcl41$412
Pyridostigmine Bromide13$397
Zolpidem Tartrate17$241
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$205
Carbidopa-LevodopaCarbidopa/Levodopa15$194
Propranolol Hcl11$164
Clonazepam15$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$551$81,47634 claims
Otsuka America Pharmaceutical, Inc.Rexulti$401$19,83112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in New Yorkon file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →